Clinical trials
Lupus Erythematosus clinical trials
Below are recruiting lupus erythematosus clinical trials, each written for real people, not researchers. We’re tracking 260 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04833465Recruiting
Testing a new outcome measure in kids with rheumatology diseases
This study looks at how to measure treatment success in children with juvenile idiopathic arthritis (JIA), lupus (SLE), or fibromyalgia (FM). It may help doctors track symptoms more reliably over time.
Washington D.C., District of ColumbiaAges 5–21 - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
Scottsdale, ArizonaAges 18–75 - NCT07180537Recruiting
Health course for joint and mood conditions
This study tests an online health course that helps improve diet and self-care to support cell health and wellbeing. It is for people with certain rheumatological conditions like rheumatoid arthritis, lupus, or psoriatic arthritis, who also have mood concerns.
Iowa City, IowaAges 18–100 - NCT03473912Recruiting
Rheumatoid disease biobank study for adults
This study asks adults with a rheumatoid condition to join a biobank, which is a safe place to store health information and biological samples for future research. It may help researchers better understand rheumatoid conditions and develop better treatments.
Kfar SabaAges 18–120 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Birmingham, AlabamaAges 18 years+ - NCT04402086Recruiting
Rheumatology patient and skin sample registry study at Yale
This study builds a health record and blood/skin sample collection for people with rheumatic autoimmune diseases who are getting care at Yale. It may help researchers understand these conditions and develop better tests or treatments over time.
New Haven, ConnecticutAges 18–99 - NCT04751396Recruiting
Melanoma education for people with autoimmune conditions
This trial tests an educational tool to help people with melanoma and pre-existing autoimmune disease understand immune checkpoint inhibitor treatment. It aims to support you and your care team with information that can help you make decisions and feel more prepared.
Houston, TexasAges 18 years+ - NCT04902807Recruiting
Tool to help decide diagnosis and treatment in immune disorders
This trial tests a tool (a way of collecting health information) to help doctors make better diagnosis, prognosis, and treatment decisions for children with certain immune problems. It also includes healthy children (like relatives) as comparison groups, to see how well the tool works.
ParisAges 1–18 - NCT04976465RecruitingPhase 1
SLE Treatment During Pregnancy Study
This Phase 1 study looks at a treatment plan for people with systemic lupus (SLE) during pregnancy and tracks health outcomes for mother and baby. It may help doctors learn how to manage SLE safely in pregnancy and what results to expect.
Jinan, ShandongAges 20–45 - NCT05007340Recruiting
ILD and autoimmune conditions registry and sample storage
This study collects health information and may store blood or other samples to learn more about interstitial lung disease (ILD) and autoimmune-related conditions. Joining could help researchers understand different causes of ILD and improve future care.
Montreal, QuebecAges 18 years+ - NCT05029336RecruitingPhase 2
Stem cell transplant using your own cells for autoimmune disease
This Phase 2 study tests an autologous stem cell transplant (a treatment using your own blood-forming stem cells) for severe systemic sclerosis or severe lupus. The goal is to reset the immune system to help control the autoimmune disease.
Philadelphia, PennsylvaniaAges 8–25 - NCT05251415Recruiting
Study of rare autoimmune diseases with blood and medical samples
This trial collects clinical and lab information (like blood and medical history) from people with rare autoimmune diseases, especially when symptoms are unusual. It aims to better understand what causes these illnesses and how newer treatments may help.
ToulouseAges 6–99 - NCT05567198Recruiting
Testing hormone shots to protect ovaries during lupus chemotherapy
This study looks at whether a monthly/3-month hormone medicine (a “GnRH shot”) can help protect ovaries in people with lupus who are treated with cyclophosphamide. It also compares this to lupus patients who do not receive the ovarian-protecting shot, using questionnaires to track outcomes.
Bethesda, MarylandAges 18–120 - NCT06189157RecruitingPhase 1/Phase 2
Testing MB-CART19.1 therapy for severe lupus
This trial tests a new type of treatment called CAR T-cell therapy (MB-CART19.1) for people with severe lupus that has not responded to other treatments. It aims to see if this therapy can help control lupus and improve organ function.
ErlangenAges 18 years+ - NCT06208514Recruiting
Brief Pain Exposure Therapy for chronic pain conditions
This study tests a type of talk therapy called Brief Pain Exposure Therapy (BPET) for people with certain chronic pain conditions like fibromyalgia, lupus, or chronic low back pain. It aims to help reduce pain by changing how your brain responds to it.
Ann Arbor, MichiganAges 18 years+ - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06316076RecruitingPhase 1
CD19 CAR-T cell therapy for autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
ShanghaiAges 18–65 - NCT06316791RecruitingEarly Phase 1
CNCT19 CAR-T therapy for refractory autoimmune diseases
This early-phase study tests a new CAR-T cell therapy (CNCT19) for people with certain autoimmune diseases that have not responded to standard treatments. It targets a protein called CD19 on immune cells to help reset the immune system and reduce disease activity.
Zhengzhou, HenanAges 18–70 - NCT06347718RecruitingPhase 1/Phase 2
Car-T cells for autoimmune disease
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
Erlangen, BavariaAges 18 years+ - NCT06379646Recruiting
YTS109 cell therapy for autoimmune disease
This study tests a new cell therapy (YTS109) for people with autoimmune diseases like lupus or Sjogren's syndrome that have not improved or keep coming back after standard treatments. It aims to see if the treatment can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06394063Recruiting
Telitacicept to prevent lupus flares
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
ShanghaiAges 18–70 - NCT06426316Recruiting
Immune cells and migraines study
This study looks at how certain immune cells and inflammatory chemicals relate to migraines. If you have migraines or an autoimmune condition (like lupus, rheumatoid arthritis, or Crohn's disease), you may be able to participate. The goal is to understand what causes migraines.
Clermont-Ferrand, AURAAges 18–50 - NCT06462768Recruiting
Study of immune cell activity in systemic sclerosis
This study looks at a specific type of immune cell activity (called neutrophil extracellular traps) in the blood of people with systemic sclerosis, other connective tissue diseases, and healthy volunteers. It aims to understand how these cells may be involved in the disease and could lead to better treatments.
ReimsAges 18 years+ - NCT06465147RecruitingPhase 1
Cell therapy for hard-to-treat lupus (REACT-01)
This trial tests a new type of cell therapy (CAR T-cells) to see if it can stop the immune system from attacking the body in severe lupus. It’s for people ages 2–30 whose lupus is not controlled by other treatments and who are willing to be treated at Seattle Children’s Hospital.
Seattle, WashingtonAges 2–30
Hear when a new Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus erythematosus?
- Yes. Clin2 currently lists 260 recruiting lupus erythematosus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus erythematosus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus erythematosus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.